PP01.114 Outcomes of Patients Diagnosed with Lung Cancer after COVID-19 Infection
Recommended Citation
Al-Saheli Z, Ammari O, Albusoul L, Abu Rous F, Gadgeel S. PP01.114 Outcomes of Patients Diagnosed with Lung Cancer after COVID-19 Infection. J Thorac Oncol 2024; 19:e49.
Document Type
Conference Proceeding
Publication Date
7-1-2024
Publication Title
J Thorac Oncol
Abstract
Background: The incidence of lung cancer (LC) has been described to be higher among patients diagnosed with COVID-19 (Lemos AEG et al). It is suggested that this is due to more imaging being performed in the setting of COVID-19 infection. In this analysis, we evaluated the outcomes of patients who were diagnosed with LC after COVID-19. Methods: This is a retrospective study including patients who were diagnosed with small cell (SCLC) and non-small cell (NSCLC) lung cancer within 6 months of their diagnosis with COVID-19 infection. Primary endpoint was overall survival (OS) defined as time from LC diagnosis to death. Secondary endpoint was progression-free survival (PFS) defined as time from LC diagnosis to progression or death. Results: A total of 86 patients were included in our analysis. Of those, 66.3%, 17.4%, 16.3% were diagnosed with non-squamous NSLCC (NSQ-NSCLC), squamous NSCLC (SQ-NSCLC), and SCLC, respectively. The mean age of patients was 70 years, 62% females and 38% males, 65% Caucasians and 23% African Americans. The mean Charlson Comorbidity Index score was 3.1 (SD of 2.2). 70.6% of patients were diagnosed with COPD. The mean smoking pack years was 42.7 years (SD 28.4) and 16.3% of patients were never smokers. Of patients with NSQ-NSCLC: 38%, 29.8%, and 31.6% had stage I-II, III, IV, respectively. Of patients with SQ-NSCLC, they were split evenly among all stages. Of patients with SCLC, most were stage IV (71.4%). Treatments received included surgery (33.7%), radiation (26.7%), chemotherapy (41.9%), immunotherapy (23.3%), and targeted therapy (4.7%). Outcomes are illustrated in Table 1. Twelve patients (14%) received a second line treatment. Conclusions: In this retrospective analysis, the percentage of patients diagnosed with early-stage NSCLC was higher than the pre-COVID incidence rate. Patients were able to receive standard of care treatments and the outcomes were consistent with their anticipated stage-adjusted survival. [Formula presented]
Volume
19
First Page
e49
